Progression from metastatic castration-sensitive (mCSPC) to castration-resistant (mCRPC) state heralds the lethal phenotype of prostate cancer. Identifying genomic alterations associated with mCRPC may help find new targets for drug development.
To describe the current scientific knowledge and clinical experience in low-grade-non-muscle-invasive bladder cancer (LG-NMIBC) patients in challenging scenarios. Medline, Embase, Google Scholar, and Cochrane Central were searched until March 2021.
To determine the potential impact of the presence of secondary variant histology on the gene expression profiles of muscle-invasive bladder cancer (MIBC) tumors. For six tumors, revised samples were collected from urothelial and secondary variant components (cohort A).
BACKGROUNDMetastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Charles Ryan: Hello, Chuck Ryan from the University of Minnesota here. I’m joined today by Dr. Oliver Sartor, who is a Professor of Medicine and the Medical Director of the Tulane Cancer Center, where he is also the C.E. and Bernadine Laborde Professor of Cancer Research, and that is, of course in New Orleans, Louisiana. […]
Alicia Morgans: Hi, my name is Alicia Morgans and I am a GU Medical Oncologist and an Associate Professor of Medicine at Northwestern University in Chicago in the U.S. I’m so excited to have here with me today Dr. Lisa Horvath, who is the Director of Research at the Chris O’Brien Lifehouse as well as […]
Charles Ryan: Hello. For virtual ASCO 2021, I’m Chuck Ryan from the University of Minnesota. I’m joined with two guests from Spain today to talk about some real-world data that they presented on the management of CRPC in that country. First off is Dr. Elena Castro, Medical Oncologist with a specialization in GU tumors, and […]
Pathological examination of image-guided tumor biopsy has been the gold standard for cancer diagnosis for decades. Nowadays, in this era of precision oncology and personalized medicine, tumor biopsy assessment has greatly expanded its roles in studying disease progression, drug efficacy, and developing biomarkers in clinical studies via performing a wide range of assays such as […]
San Francisco, CA (UroToday.com) — A new study by researchers at Fox Chase Cancer Center found that patients with muscle-invasive bladder cancer can safely receive chemotherapy, even when their tumors are blocking their kidneys. The findings mean that patients with the most serious form of this common cancer can receive potentially life-extending treatment, usually without the […]
Introduction: For maximum utility of molecular characterization by next-generation sequencing (NGS) and better understanding of tumor microenvironment with immune correlates analysis, biopsy specimens must yield adequate tumor tissue, and sequential biopsy specimens should sample a consistent site. We developed a web-based lesion selection tool (LST) that enables management and tracking of the biopsy specimen collections.
